DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. compan ...

Core Insights - Amarin Corporation presented findings on the efficacy of VASCEPA/VAZKEPA in reducing Major Adverse Cardiovascular Events (MACE) in patients with varying Lipoprotein(a) [Lp(a)] levels and irrespective of baseline LDL-C levels [1][2][4] Group 1: Efficacy of VASCEPA/VAZKEPA - The analysis showed that high Lp(a) concentrations correlate with increased cardiovascular event risk, even when LDL-C levels are managed [2][4] - In a post hoc analysis of the REDUCE-IT study, 7,026 patients were evaluated, revealing a significant relationship between baseline Lp(a) levels and MACE risk, independent of LDL-C and triglycerides [3][4] - Icosapent ethyl (IPE) demonstrated a relative risk reduction of 21% for patients with Lp(a) ≥50 mg/dL and 25% for those with Lp(a) <50 mg/dL [5][4] Group 2: LDL-C and Cardiovascular Outcomes - The study also assessed the impact of IPE on cardiovascular outcomes among patients with different baseline LDL-C levels, specifically those below and above 55 mg/dL [6][7] - Among patients with LDL-C <55 mg/dL, the primary outcome rate was 16.2% in the IPE group compared to 22.8% in the placebo group, indicating a hazard ratio (HR) of 0.66 [7] - For patients with LDL-C ≥55 mg/dL, the rates were 17.4% in the IPE group versus 21.9% in the placebo group, with an HR of 0.76, showing consistent efficacy across both LDL-C subgroups [7][8] Group 3: Study Background and Significance - The REDUCE-IT study was a global cardiovascular outcomes trial involving 8,179 patients, designed to evaluate the effect of VASCEPA in high-risk patients with controlled LDL-C levels [10][11] - The findings reinforce the clinical benefit of IPE in reducing cardiovascular events, particularly in patients with elevated triglycerides and varying Lp(a) levels [5][8] - Amarin aims to enhance the understanding of cardiovascular risk management beyond traditional therapies, emphasizing the importance of ongoing research in this area [2][9]

Core Insights - Amarin Corporation's shares increased by 7.1% following positive updates regarding its intellectual property for Vazkepa in Europe [1] - A new patent from the European Patent Office extends Vazkepa's regulatory exclusivity until April 2039, adding eight years of commercial protection [2] - The validity of another existing patent for Vazkepa was upheld, which is crucial for maintaining competitive pricing in the healthcare sector [2] - Year-to-date, Amarin's shares have risen by 21.8%, significantly outperforming the industry average of 1.9% [3] Patent and Exclusivity - The new patent and the upheld patent claims are based on results from the REDUCE-IT study, which demonstrated that Vazkepa reduces cardiovascular death and revascularization risks [2] - The exclusivity granted by these patents allows Amarin to set drug prices without competition, which is vital for revenue generation [2] Market Performance - Vazkepa is approved in Europe for reducing cardiovascular event risks and as an add-on treatment for adults with high triglyceride levels [3] - The drug is also marketed in the U.S. under the name Vascepa, but has faced generic competition since 2020, leading to a 22% decline in sales last year [4] - Amarin has not provided revenue guidance for 2024 due to uncertainty regarding the impact of generic competition [4] Competitive Landscape - The company faces challenges in raising awareness for Vazkepa's cardiovascular risk reduction indication, which may further affect sales [4] - Other healthcare stocks with strong performance include ADMA Biologics, ANI Pharmaceuticals, and Ligand Pharmaceuticals, each showing significant earnings surprises and share price increases [5][6][7]

There was unambigously good news about the company's single commercialized medication.Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (AMRN 7.07%), which received very encouraging news about its single commercialized drug that day. As a result, its shares were trading more than 6% higher in late-session trading on the stock market, eclipsing the basically flatlining S&P 500 index.A victory for VazkepaAmarin announced t ...

DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office (EPO) for a new patent covering VAZKEPA® (icosapent ethyl) that will extend VAZKEPA exclusivity eight additional years into 2039. In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO. Collectively, these patents cover bot ...

Amarin Corporation Plc (AMRN) reported break-even quarterly earnings in fourth-quarter 2023 against the Zacks Consensus Estimate of a loss of 4 cents per share. The company recorded adjusted earnings of 2 cents in the year-ago quarter.Adjusted earnings exclude non-cash stock-based compensation, restructuring inventory and other restructuring expenses.Total revenues were $74.7 million, beating the Zacks Consensus Estimate of $72.5 million. However, revenues were down 17% from the year-ago quarter’s levels, o ...

Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Conference Call February 29, 2024 8:00 AM ET Company Participants Mark Marmur - Vice President, Global Corporate Communications Patrick Holt - President and Chief Executive Officer Tom Reilly - Executive Vice President, Chief Financial Officer and Head of Global HR & Finance Conference Call Participants Roanna Ruiz - Leerink Partners Operator Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2023 Financial Result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-21392 | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------|-------------- ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A. The conference call with management will follow the release of the Company's fourth quar ...

It has been a rather lukewarm earnings season for the drug and biotech sector. Majority of large drug/biotech companies reported mixed results and issued fresh guidance for 2024, which was largely optimistic. Several smaller biotechs are scheduled to report earnings results this month.Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.Per the Earnings Trends report, as of Feb 14, 80.0% of the Me ...